Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch1 of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial. Glenmark’s Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial of Fresenius Kabi USA, LLC. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.
